A detailed history of Charles Schwab Investment Management Inc transactions in Cel Sci Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 16,481 shares of CVM stock, worth $11,536. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,481
Previous 16,481 -0.0%
Holding current value
$11,536
Previous $19,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$2.58 - $4.99 $202,088 - $390,861
-78,329 Reduced 82.62%
16,481 $75,000
Q1 2022

May 13, 2022

BUY
$3.93 - $7.7 $1,257 - $2,464
320 Added 0.34%
94,810 $373,000
Q3 2021

Nov 16, 2021

BUY
$7.64 - $12.49 $21,216 - $34,684
2,777 Added 3.03%
94,490 $1.04 Million
Q2 2021

Aug 16, 2021

BUY
$8.68 - $27.49 $17,325 - $54,870
1,996 Added 2.22%
91,713 $797,000
Q1 2021

May 17, 2021

BUY
$12.0 - $27.64 $68,640 - $158,100
5,720 Added 6.81%
89,717 $1.37 Million
Q4 2020

Feb 16, 2021

BUY
$11.05 - $16.62 $3,303 - $4,969
299 Added 0.36%
83,997 $980,000
Q3 2020

Nov 13, 2020

SELL
$11.69 - $14.54 $19,721 - $24,528
-1,687 Reduced 1.98%
83,698 $1.07 Million
Q2 2020

Aug 14, 2020

SELL
$9.75 - $17.6 $13,776 - $24,868
-1,413 Reduced 1.63%
85,385 $1.27 Million
Q1 2020

May 15, 2020

BUY
$7.54 - $17.05 $99,249 - $224,429
13,163 Added 17.88%
86,798 $1 Million
Q3 2019

Nov 08, 2019

BUY
$6.0 - $9.6 $18,714 - $29,942
3,119 Added 4.42%
73,635 $659,000
Q2 2019

Aug 09, 2019

BUY
$3.77 - $8.67 $206,833 - $475,662
54,863 Added 350.5%
70,516 $591,000
Q1 2019

May 14, 2019

BUY
$2.58 - $3.54 $40,384 - $55,411
15,653 New
15,653 $56,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $30.4M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.